Cathepsin L targeting in cancer treatment

Dhivya R. Sudhan; Dietmar W. Siemann

doi:10.1016/j.pharmthera.2015.08.007

Cathepsin L targeting in cancer treatment

Dhivya R. Sudhan, Dietmar W. Siemann

Research output: Contribution to journal › Review article › peer-review

120 Scopus citations

Abstract

Proteolytic enzymes may serve as promising targets for novel therapeutic treatment strategies seeking to impede cancer progression and metastasis. One such enzyme is cathepsin L (CTSL), a lysosomal cysteine protease. CTSL upregulation, a common occurrence in a variety of human cancers, has been widely correlated with metastatic aggressiveness and poor patient prognosis. In addition, CTSL has been implicated to contribute to cancer-associated osteolysis, a debilitating morbidity affecting both life expectancy and the quality of life. In this review, we highlight the mechanisms by which CTSL contributes to tumor progression and dissemination and discuss the therapeutic utility of CTSL intervention strategies aimed at impeding metastatic progression and bone resorption.

Original language	English (US)
Pages (from-to)	105-116
Number of pages	12
Journal	Pharmacology and Therapeutics
Volume	155
DOIs	https://doi.org/10.1016/j.pharmthera.2015.08.007
State	Published - Nov 2015
Externally published	Yes

Keywords

Bone resorption
Cancer
Cathepsin L
Metastasis
Protease targeting

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1016/j.pharmthera.2015.08.007

Cite this

@article{384bcc537a1141cf8c0d26261931e72a,

title = "Cathepsin L targeting in cancer treatment",

abstract = "Proteolytic enzymes may serve as promising targets for novel therapeutic treatment strategies seeking to impede cancer progression and metastasis. One such enzyme is cathepsin L (CTSL), a lysosomal cysteine protease. CTSL upregulation, a common occurrence in a variety of human cancers, has been widely correlated with metastatic aggressiveness and poor patient prognosis. In addition, CTSL has been implicated to contribute to cancer-associated osteolysis, a debilitating morbidity affecting both life expectancy and the quality of life. In this review, we highlight the mechanisms by which CTSL contributes to tumor progression and dissemination and discuss the therapeutic utility of CTSL intervention strategies aimed at impeding metastatic progression and bone resorption.",

keywords = "Bone resorption, Cancer, Cathepsin L, Metastasis, Protease targeting",

author = "Sudhan, {Dhivya R.} and Siemann, {Dietmar W.}",

note = "Funding Information: The authors' work is supported by the National Cancer Institute (Public Health Service grant R01 CA169300 ). Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = nov,

doi = "10.1016/j.pharmthera.2015.08.007",

language = "English (US)",

volume = "155",

pages = "105--116",

journal = "Pharmacology and Therapeutics",

issn = "0163-7258",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Cathepsin L targeting in cancer treatment

AU - Sudhan, Dhivya R.

AU - Siemann, Dietmar W.

PY - 2015/11

Y1 - 2015/11

N2 - Proteolytic enzymes may serve as promising targets for novel therapeutic treatment strategies seeking to impede cancer progression and metastasis. One such enzyme is cathepsin L (CTSL), a lysosomal cysteine protease. CTSL upregulation, a common occurrence in a variety of human cancers, has been widely correlated with metastatic aggressiveness and poor patient prognosis. In addition, CTSL has been implicated to contribute to cancer-associated osteolysis, a debilitating morbidity affecting both life expectancy and the quality of life. In this review, we highlight the mechanisms by which CTSL contributes to tumor progression and dissemination and discuss the therapeutic utility of CTSL intervention strategies aimed at impeding metastatic progression and bone resorption.

AB - Proteolytic enzymes may serve as promising targets for novel therapeutic treatment strategies seeking to impede cancer progression and metastasis. One such enzyme is cathepsin L (CTSL), a lysosomal cysteine protease. CTSL upregulation, a common occurrence in a variety of human cancers, has been widely correlated with metastatic aggressiveness and poor patient prognosis. In addition, CTSL has been implicated to contribute to cancer-associated osteolysis, a debilitating morbidity affecting both life expectancy and the quality of life. In this review, we highlight the mechanisms by which CTSL contributes to tumor progression and dissemination and discuss the therapeutic utility of CTSL intervention strategies aimed at impeding metastatic progression and bone resorption.

KW - Bone resorption

KW - Cancer

KW - Cathepsin L

KW - Metastasis

KW - Protease targeting

UR - http://www.scopus.com/inward/record.url?scp=84945460903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945460903&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2015.08.007

DO - 10.1016/j.pharmthera.2015.08.007

M3 - Review article

C2 - 26299995

AN - SCOPUS:84945460903

SN - 0163-7258

VL - 155

SP - 105

EP - 116

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

ER -

Cathepsin L targeting in cancer treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this